浙江寿仙谷医药股份有限公司 重大信息内部报告制度 二〇二五年八月（修订） | 第一章 总则 . | | --- | | 第二章 重大信息的范围 | | 第三章 重大信息内部报告程序 . | | 第四章 保密义务及法律责任 | | 第五章 附则 10 | 第一章 总则 第一条 为规范浙江寿仙谷医药股份有限公司（以下简称"公司"）的重大 信息内部报告工作，保证公司内部重大信息的快速传递、归集和有效管理，及时、 准确、全面、完整地披露信息，维护投资者的合法权益，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上海证券交易所股票上市规则》、《上市公司信息披露管 理办法》、《浙江寿仙谷医药股份有限公司章程》（以下简称"《公司章程》"） 等法规规章及中国证监会、证券交易所有关规定和要求，结合公司实际，制定本 制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公 司证券及其衍生品种的交易价格产生较大影响的情形或事件时，按照本制度规定 负有报告义务的有关人员和公司（以下简称"信息报告义务人"），应在第一时 间将相关信息向公司董事长、董事会 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company achieved operating revenue of 299.68 million yuan, representing a year-on-year decrease of 16.51% [1] - The net profit attributable to shareholders was 65.56 million yuan, down 33.99% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 35.82 million yuan, reflecting a year-on-year decline of 57.65% [1]

[Glossary](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) This section defines key terms and identifies the company, its subsidiaries, controlling shareholder, and actual controllers - The report defines "Company," "the Company," and "Shouxian Valley" as Zhejiang Shouxian Valley Pharmaceutical Co., Ltd., listing several wholly-owned and associate companies[14](index=14&type=chunk) - The controlling shareholder is Zhejiang Shouxian Valley Investment Management Co., Ltd., and the actual controllers are the Li Mingyan family (Li Mingyan, Zhu惠照, Li Zhenhao, Li Zhenyu)[14](index=14&type=chunk) - Key terms such as Chinese medicinal materials, decoction pieces, proprietary Chinese medicines, health foods, Ganoderma lucidum spore powder, Dendrobium officinale, GMP, direct stores, and distributors are explained[14](index=14&type=chunk)[15](index=15&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides an overview of the company's basic information and presents key financial performance metrics - The company's Chinese name is Zhejiang Shouxian Valley Pharmaceutical Co., Ltd., stock code **603896**, listed on the Shanghai Stock Exchange[17](index=17&type=chunk)[21](index=21&type=chunk) - The company's legal representative is Li Mingyan, and the Board Secretary is Liu Guofang[17](index=17&type=chunk)[18](index=18&type=chunk) - The company's registered address is No. 10 Shangcheng Road, Hushan Street, Wuyi County, Zhejiang Province, with the website www.sxg1909.com[19](index=19&type=chunk) [Company's Key Accounting Data and Financial Indicators](index=7&type=section&id=%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) Operating revenue and net profit significantly declined year-on-year, while total assets and net assets attributable to shareholders slightly increased Key Financial Performance Indicators | Indicator | Current Period (Jan-Jun) | Prior Period (Adjusted) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 299,683,685.70 | 358,941,052.69 | -16.51 | | Total Profit | 65,695,913.28 | 99,325,142.76 | -33.86 | | Net Profit Attributable to Listed Company Shareholders | 65,558,637.69 | 99,310,066.78 | -33.99 | | Net Profit Attributable to Listed Company Shareholders excl. Non-recurring G&L | 35,824,360.12 | 84,599,684.53 | -57.65 | | Net Cash Flow from Operating Activities | 122,994,078.52 | 129,175,435.64 | -4.79 | | **Current Period End vs Prior Year End (Adjusted)** | | | | | Net Assets Attributable to Listed Company Shareholders | 2,311,679,934.95 | 2,291,287,346.15 | 0.89 | | Total Assets | 3,263,637,736.15 | 3,131,807,017.80 | 4.21 | Per Share Data and Profitability Ratios | Indicator | Current Period (Jan-Jun) | Prior Period (Adjusted) | Change (%) | | :--- | :--- | :--- | :--- | | Basic EPS (RMB/share) | 0.33 | 0.50 | -34.00 | | Diluted EPS (RMB/share) | 0.33 | 0.50 | -34.00 | | Basic EPS excl. Non-recurring G&L (RMB/share) | 0.18 | 0.43 | -58.14 | | Weighted Average ROE (%) | 2.82 | 4.46 | YoY decrease of 1.64 percentage points | | Weighted Average ROE excl. Non-recurring G&L (%) | 1.54 | 3.80 | YoY decrease of 2.26 percentage points | - The decline in operating revenue is primarily due to weak consumption, but **Q2's 6.64% year-on-year decrease** improved significantly from **Q1's 22.68% decrease**, with **positive growth achieved in July**[25](index=25&type=chunk) - Net profit declined more sharply than operating revenue, mainly due to increased management and financial expenses; management expenses rose by **RMB 3.32 million** (depreciation increased by **RMB 5.06 million**), and financial expenses increased by **RMB 17.48 million** (due to a **RMB 15.88 million** decrease in interest income)[26](index=26&type=chunk) [Non-recurring Gains and Losses Items and Amounts](index=8&type=section&id=%E4%B9%9D%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) Total non-recurring gains and losses for the period were **RMB 29,734,277.57**, mainly from government subsidies and financial asset fair value changes Non-recurring Gains and Losses Items | Non-recurring Gains and Losses Item | Amount (RMB) | | :--- | :--- | | Government subsidies included in current profit and loss | 24,809,410.27 | | Fair value changes and disposal gains/losses from financial assets and liabilities held by non-financial enterprises, excluding effective hedge accounting related to normal business operations | 4,392,313.34 | | Other non-operating income and expenses apart from the above items | 580,507.78 | | Total | 29,734,277.57 | [Management Discussion and Analysis](index=9&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section discusses the company's industry, business operations, core competencies, and financial performance during the reporting period - The company primarily engages in the breeding, cultivation, processing, and sales of precious Chinese medicinal materials such as Ganoderma lucidum, Dendrobium officinale, and saffron[31](index=31&type=chunk) - During the reporting period, the company's operating revenue decreased by **16.51%** year-on-year, and net profit attributable to parent company shareholders decreased by **33.99%** year-on-year[55](index=55&type=chunk) - The company continues to advance its "full industrial chain" development model, possessing core advantages in breeding, cultivation, standard setting, and Ganoderma lucidum spore powder cell-wall breaking and de-walling processes[64](index=64&type=chunk)[67](index=67&type=chunk)[74](index=74&type=chunk)[75](index=75&type=chunk)[77](index=77&type=chunk) [Explanation of the Company's Industry and Main Business Operations during the Reporting Period](index=9&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E5%8F%8A%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) This section outlines the company's main businesses, operating models, and industry trends for Chinese medicinal products and health foods - The company's core products include Shouxian Valley brand Ganoderma lucidum spore powder (cell-wall broken/de-walled), Dendrobium candidum granules, and Dendrobium candidum Ganoderma lucidum extract[31](index=31&type=chunk) - The operating model encompasses self-production at bases, external procurement of raw materials, and product distribution and direct sales (including internet sales)[34](index=34&type=chunk)[35](index=35&type=chunk)[37](index=37&type=chunk)[39](index=39&type=chunk)[41](index=41&type=chunk) - The Chinese medicinal decoction pieces market grew to **RMB 276.4 billion** in 2024, projected to exceed **RMB 300 billion** in 2025, driven by policy support and digital transformation[45](index=45&type=chunk) - The health food market reached **RMB 399.8 billion** in 2024, expected to surpass **RMB 1.5 trillion** by 2030, with young consumers and segmented categories as key growth drivers[46](index=46&type=chunk)[47](index=47&type=chunk) - The Ganoderma lucidum and Ganoderma lucidum spore powder industry has varying technical content and quality, but the company is the **sole enterprise mastering de-walling technology** and has led the formulation of **ISO international standards**[50](index=50&type=chunk)[51](index=51&type=chunk) - The Dendrobium officinale industry shows clear regional distribution, with Zhejiang enterprises holding a leading edge in deep processing and sales[53](index=53&type=chunk) [Discussion and Analysis of Operations](index=13&type=section&id=%E4%BA%8C%E3%80%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) The company actively implemented marketing reforms, digital empowerment, and R&D innovation, advancing construction projects despite revenue and net profit declines - In the first half of 2025, the company achieved operating revenue of **RMB 299.6837 million**, a year-on-year decrease of **16.51%**; net profit attributable to listed company shareholders was **RMB 65.5586 million**, a year-on-year decrease of **33.99%**[55](index=55&type=chunk) - The company established a multi-dimensional operating model through various channels, expanding into markets outside Zhejiang, successfully signing **7 strategic partners**, acquiring **10 health pharmacies**, opening **5 new direct stores**, and signing over **110 new cooperative terminals**[57](index=57&type=chunk) - The company fully advanced its "Future Farm + Future Factory + Future Market" digital intelligence construction, with MES, WMS, DIMS, SFA, and other systems launched, driving sales operations to transition from **"experience-based decision-making" to "data-driven decision-making"**[59](index=59&type=chunk) - There are **92 R&D projects** underway, including **56 industry-academia collaboration projects**, with multiple provincial and ministerial awards received; the Ganoderma germplasm bank was certified by Guinness as the **"world's largest Ganoderma germplasm bank"**[60](index=60&type=chunk)[61](index=61&type=chunk) - The Yanglong Phase III civil engineering project successfully completed final acceptance, and the Shouxian Valley Health Bio-industrial Park soft capsule preparation workshop obtained its production license, now possessing qualifications for producing **five major health food dosage forms**[62](index=62&type=chunk) - Two new products (Ganoderma whole herb tablets, Ginseng Ganoderma tablets) using **"de-walled Ganoderma lucidum spore powder"** as raw material successfully completed registration acceptance, and one product (Shouxian Valley brand Saffron Dendrobium candidum paste) obtained renewed registration[63](index=63&type=chunk) [Analysis of Core Competitiveness during the Reporting Period](index=15&type=section&id=%E4%B8%89%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) Core competitiveness derives from its "full industrial chain" model, superior breeding, organic cultivation, industry standard leadership, unique processing, regional advantages, and robust quality control - The company has established a **"full industrial chain"** development model for Ganoderma lucidum, Dendrobium officinale, and other product series, covering breeding, cultivation, processing, and sales, thereby strengthening control over distribution channels[64](index=64&type=chunk)[65](index=65&type=chunk)[66](index=66&type=chunk) - The company possesses a rare Chinese medicinal material germplasm resource bank, independently breeding **"Xianzhi" series Ganoderma lucidum** and **"Xianhu" series Dendrobium officinale** new varieties, and has received multiple provincial and national awards[67](index=67&type=chunk)[70](index=70&type=chunk)[72](index=72&type=chunk) - The company holds a leading position in the technical R&D and industry standard setting for Ganoderma lucidum and Dendrobium officinale, having led or participated in the formulation of **63 published standards, including 4 international standards**[75](index=75&type=chunk) - The company pioneered the **"four low, one high" supersonic low-temperature airflow cell-wall breaking technology** and invented the spore powder de-walling technology, significantly increasing the content and safety of active ingredients[78](index=78&type=chunk) - The company's management and R&D teams remain stable; Chairman Li Mingyan has over **40 years of industry experience** in Chinese medicinal material breeding and decoction piece R&D, and the company hosts the **"Shouxian Valley Academician Expert Workstation"** and a **"Provincial Post-doctoral Workstation"**[84](index=84&type=chunk)[85](index=85&type=chunk) [Main Operating Conditions during the Reporting Period](index=22&type=section&id=%E5%9B%9B%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E4%B8%BB%E8%A6%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5) This section analyzes changes in key financial statement items, main business revenue breakdown, gross profit and margin, and asset-liability and investment status Key Income Statement Items and Changes | Item | Current Period (RMB) | Prior Period (RMB) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 299,683,685.70 | 358,941,052.69 | -16.51 | Weak consumption | | Operating Cost | 57,512,042.40 | 70,433,361.35 | -18.35 | Linked to revenue decrease | | Sales Expenses | 133,095,100.94 | 159,034,297.14 | -16.31 | Decreased advertising expenses | | Management Expenses | 45,874,434.56 | 42,555,057.12 | 7.80 | Increased depreciation expenses | | Financial Expenses | 1,776,526.77 | -15,709,351.78 | Not applicable | Decreased interest income | | R&D Expenses | 29,763,574.38 | 23,165,012.10 | 28.49 | Increased R&D investment | | Net Cash Flow from Investing Activities | -122,875,258.16 | 285,259,358.54 | -143.07 | Larger amount of wealth management products matured in prior period | Main Business Revenue Breakdown | Item | Amount (RMB 10,000) | Proportion (%) | Growth Rate (%) | | :--- | :--- | :--- | :--- | | Main Business Revenue | 29,478.96 | 98.37 | -16.44 | | Ganoderma Lucidum Spore Powder Products | 21,553.64 | 73.11 | -17.79 | | Dendrobium Officinale Products | 4,666.25 | 15.83 | -24.25 | | Sales in Zhejiang Province | 19,461.46 | 66.47 | -23.72 | | Internet Sales | 7,678.30 | 25.60 | 15.14 | | Distribution Model Subtotal | 15,575.81 | 52.84 | -26.88 | | Direct Sales Model Subtotal | 13,903.15 | 47.16 | -0.55 | Gross Profit Margin by Product | Product | Gross Margin (%) | YoY Change (percentage points) | | :--- | :--- | :--- | | Ganoderma Lucidum Spore Powder Products | 85.57 | 0.29 | | Dendrobium Officinale Products | 81.21 | 2.58 | | Other Products | 65.41 | 2.65 | | Total | 82.65 | 0.66 | Key Balance Sheet Items and Changes | Item Name | Current Period End (RMB) | Change from Prior Year End (%) | Explanation of Change | | :--- | :--- | :--- | :--- | | Accounts Receivable | 54,234,289.44 | -33.68 | Decreased sales revenue, intensified collection efforts | | Inventory | 224,978,555.16 | 23.82 | Increase in consumable biological assets | | Fixed Assets | 720,576,250.47 | 110.01 | Construction in progress transferred to fixed assets | | Construction in Progress | 242,060,370.10 | -51.75 | Construction in progress transferred to fixed assets | | Short-term Borrowings | 262,919,600.20 | 40.30 | Increased bill discounting business | | Contract Liabilities | 13,906,276.55 | 31.64 | Increased advance receipts for goods | - Total external equity investments at period-end amounted to **RMB 108,466,247.07**, primarily including investments in Wuyi Commercial Bank, Wuyi BOC Fullerton Bank, and Qingyu Shouxian Valley[108](index=108&type=chunk) - During the reporting period, the company acquired **100% equity** of Hangzhou Shouxian Valley Health Pharmacy Chain Co., Ltd. to integrate assets and enhance scale and revenue levels[109](index=109&type=chunk) [Other Disclosures](index=32&type=section&id=%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E6%8A%AB%E9%9C%B2%E4%BA%8B%E9%A1%B9) This section discloses potential risks like natural disasters, gross margin volatility, and inventory turnover, alongside progress on the "Quality Improvement, Efficiency Enhancement, and Return" action plan - The company may face risks such as natural disasters, gross margin fluctuations, license cancellation, raw material quality control, germplasm loss, tax policy changes, and slow inventory turnover[110](index=110&type=chunk)[111](index=111&type=chunk)[112](index=112&type=chunk)[113](index=113&type=chunk)[115](index=115&type=chunk)[116](index=116&type=chunk)[117](index=117&type=chunk) - The "Quality Improvement, Efficiency Enhancement, and Return" action plan is progressing smoothly, including focusing on core business, technological innovation (**4 authorized invention patents**, Guinness certification for Ganoderma germplasm bank, **ESG rating upgraded to AA**)[118](index=118&type=chunk)[119](index=119&type=chunk) - The company prioritizes investor returns, with annual cash dividends consistently **above 30%** since its listing; **RMB 53,525,855.97** was distributed as cash dividends for the 2024 fiscal year[120](index=120&type=chunk) - Mr. Li Zhenyu, one of the actual controllers, Director, and General Manager, increased his shareholding by **3,964,800 shares**, representing **2.00%** of the total share capital, with a cumulative increase amount of **RMB 82.0992 million**[121](index=121&type=chunk) - The company strengthens investor relations management through various channels such as performance briefings, "SSE E-interaction," and investor hotlines, achieving a **100% response rate**[122](index=122&type=chunk) [Corporate Governance, Environment, and Society](index=35&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) This section reports on the stability of the board and management, absence of profit distribution plans, and continuous efforts in environmental protection and pollution control - During the reporting period, there were no changes in the company's directors, supervisors, or senior management, and no half-year profit distribution or capital reserve to share capital plans[124](index=124&type=chunk) - The company is not classified as a key polluting entity but continuously invests in the construction and operation of pollution prevention facilities, including those for water, air, noise, and solid waste treatment[125](index=125&type=chunk)[126](index=126&type=chunk) - The company formulated a 2025 self-monitoring plan for "three wastes" (wastewater, waste gas, solid waste), regularly commissioning third parties for testing to ensure emissions comply with national environmental standards[127](index=127&type=chunk)[128](index=128&type=chunk) [Significant Matters](index=38&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section details the fulfillment of commitments, related party transactions, asset acquisitions, construction projects, and convertible bond issuance and fund utilization - The controlling shareholder, actual controllers, directors, supervisors, and senior management have all strictly fulfilled their commitments regarding resolving horizontal competition, related party transactions, and supplementary payments for social insurance and housing provident funds[131](index=131&type=chunk)[132](index=132&type=chunk)[133](index=133&type=chunk)[134](index=134&type=chunk) - The estimated total amount of routine related party transactions for 2025 is **RMB 616.58 million** (including **RMB 550 million** in related party deposits), with **RMB 551.9039 million** actually incurred in the first half[137](index=137&type=chunk)[138](index=138&type=chunk) - The company, through its wholly-owned subsidiary, acquired **100% equity** of Hangzhou Shouxian Valley Health Pharmacy Chain Co., Ltd. from the controlling shareholder for a consideration of **RMB 3.30 million**, with the industrial and commercial change completed[139](index=139&type=chunk) - The construction general contract for the Shouxian Valley Digital Intelligence Center project has a provisional total price of **RMB 350 million**, with **RMB 62.7329 million** paid as of the end of the reporting period[141](index=141&type=chunk) - The company issued two convertible bonds totaling **RMB 758 million** (net **RMB 736 million**); the "Health Industrial Park Health Food Phase II Project" was suspended, and **RMB 80.5320 million** of raised funds were reallocated to the "Smart Park Upgrade Project"[143](index=143&type=chunk)[144](index=144&type=chunk)[145](index=145&type=chunk) - As of the end of the reporting period, cumulative raised funds invested amounted to **RMB 521 million**, with the "Health Industrial Park Health Food Project (Basic Construction)" achieving a progress of **97.83%**. The company managed idle raised funds through cash management, with an ending balance of **RMB 224.83 million**[146](index=146&type=chunk)[149](index=149&type=chunk) [Share Changes and Shareholder Information](index=48&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section reports on minor changes in total shares due to convertible bond conversion, lists top shareholders, and confirms the actual control structure - During the reporting period, the company's total shares increased from **198,243,832 shares** to **198,243,911 shares**, an increase of **79 shares**, primarily due to the conversion of "Shou 22 Convertible Bonds"[152](index=152&type=chunk)[153](index=153&type=chunk) - As of the end of the reporting period, the total number of common shareholders was **23,739**[155](index=155&type=chunk) Top Shareholders | Shareholder Name | Shares Held at Period End (shares) | Proportion (%) | Shareholder Type | | :--- | :--- | :--- | :--- | | Zhejiang Shouxian Valley Investment Management Co., Ltd. | 56,711,239 | 28.61 | Domestic Non-State-owned Legal Person | | Li Zhenhao | 15,041,650 | 7.59 | Domestic Natural Person | | Li Zhenyu | 9,078,961 | 4.58 | Domestic Natural Person | | Xu Meiyun | 2,833,900 | 1.43 | Domestic Natural Person | | Fang Zhengshun | 2,600,100 | 1.31 | Domestic Natural Person | - The actual controllers, the Li Mingyan family (Li Mingyan, Zhu Huizhao, Li Zhenhao, Li Zhenyu), collectively hold **40.78%** of the company's equity[158](index=158&type=chunk) - Mr. Li Zhenyu, Director and General Manager, increased his shareholding by **3,964,800 shares** during this period[157](index=157&type=chunk)[160](index=160&type=chunk) [Bond-Related Information](index=53&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) This section provides details on the company's convertible bonds, including issuance, conversion status, and credit ratings - The company issued two convertible corporate bonds: "Shouxian Convertible Bond" (redeemed and delisted on June 6, 2023) and "Shou 22 Convertible Bond"[162](index=162&type=chunk)[163](index=163&type=chunk) - The "Shou 22 Convertible Bond" had a total issuance amount of **RMB 398 million**, a 6-year term, with a conversion period from May 23, 2023, to November 16, 2028[163](index=163&type=chunk)[164](index=164&type=chunk) - As of the end of the reporting period, **8,150 shares** of "Shou 22 Convertible Bond" had been converted, with an unconverted amount of **RMB 397,689,000**, representing **99.92%** of the total issuance[168](index=168&type=chunk) - The conversion price of "Shou 22 Convertible Bond" has been adjusted multiple times, with the latest conversion price at **RMB 36.84/share** as of the end of the reporting period[170](index=170&type=chunk) - As of June 30, 2025, the company's total assets were **RMB 3,263.8735 million**, with an asset-liability ratio of **29.17%**. The company's main credit rating is **"AA-"**, and the "Shou 22 Convertible Bond" rating is **"AA-"**, with a **"stable"** outlook[171](index=171&type=chunk) [Financial Report](index=56&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section presents the company's consolidated and parent company financial statements, significant accounting policies, and changes in consolidation scope - This section includes the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owner's equity[174](index=174&type=chunk)[178](index=178&type=chunk)[181](index=181&type=chunk)[184](index=184&type=chunk)[187](index=187&type=chunk)[190](index=190&type=chunk)[193](index=193&type=chunk)[198](index=198&type=chunk) - Detailed disclosure of significant accounting policies and accounting estimates, covering accounting treatments for financial instruments, inventory, long-term equity investments, fixed assets, and revenue recognition[206](index=206&type=chunk)[211](index=211&type=chunk)[236](index=236&type=chunk)[241](index=241&type=chunk)[249](index=249&type=chunk)[256](index=256&type=chunk)[276](index=276&type=chunk)[286](index=286&type=chunk) - Explanation of changes in the scope of consolidation for the current period, including the acquisition of **100% equity** of Hangzhou Shouxian Valley Health Pharmacy Chain Co., Ltd. through a business combination under common control, the establishment of Hangzhou Shouxian Valley Food Co., Ltd., and the transfer of Fuzhou Shouxian Valley Health Management Co., Ltd. and Zhengzhou Shouxian Valley Health Management Co., Ltd.[162](index=162&type=chunk)[484](index=484&type=chunk)[490](index=490&type=chunk)[491](index=491&type=chunk) - Disclosure of risks related to financial instruments, including credit risk, liquidity risk, and market risk (interest rate risk, other price risk), along with an analysis of the maturity dates of undiscounted contractual cash flows for financial liabilities[500](index=500&type=chunk)[501](index=501&type=chunk)[503](index=503&type=chunk)[504](index=504&type=chunk)

Group 1 - The core point of the announcement indicates that the company, Shouxiangu, reported a revenue of 300 million yuan for the first half of 2025, representing a year-on-year decline of 16.51% [1] - The net profit for the same period was 65.5586 million yuan, which reflects a year-on-year decrease of 33.99% [1]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-054 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 | 转债 22 | | 浙江寿仙谷医药股份有限公司 关于追加 2025 年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）本次追加日常关联交易预计额度履行的审议程序和专项意见 本次增加日常关联交易事项已经浙江寿仙谷医药股份有限公司（以下简称 "公司"或"寿仙谷"）第五届董事会独立董事专门会议 2025 年第一次会议、第 五届董事会审计委员会 2025 年第一次会议、第五届监事会第二次会议、第五届 董事会第二次会议审议通过。关联董事李明焱先生、李振皓先生和李振宇先生对 该项议案回避表决。本次增加日常关联交易事项无需提交公司股东大会审议。 公司第五届董事会独立董事专门会议 2025 年第一次会议审议通过了《关于 追加 2025 年度日常关联交易预计额度的议案》，独立董事 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-053 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司募集 资金监管规则》、上海证券交易所《上市公司自律监管指引第 1 号——规范运作》 《上市公司自律监管指南第 1 号——公告格式》等有关规定，现将浙江寿仙谷医 药股份有限公司（以下简称"公司"或"寿仙谷"）2025 年半年度募集资金存放与使 用情况专项说明如下： 一、募集资金基本情况 （一）2020 年公开发行可转换公司债券募集资金 1、实际募集资金金额和资金到账时间 经中国证监会《关于核准浙江寿仙谷医药股份有限公司公开发行可转换公司 债券的批复》（证监许可[2020] 658 号）核准，公司已公开发行总额为人民币 36,000 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-055 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于变更公司注册资本、取消监事会暨修订《公司章 程》及废止、修订和制定部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江寿仙谷医药股份有限公司（以下简称"公司"）第五届董事会第二次会 议于 2025 年 8 月 27 日召开，审议通过了《关于变更公司注册资本、取消监事会 暨修订<公司章程>的议案》及《关于修订部分公司治理制度的议案》。具体情况 如下： 一、注册资本变动情况 经中国证券监督管理委员会"证监许可[2022]2165 号"文核准，公司于 2022 年 11 月 17 日公开发行 398 万张可转换公司债券，每张面值 100 元，发行总额 39,800 万元。经上海证券交易所自律监管决定书[2022]332 号文同意，公司 39,800.00 万元可转债于 20 ...

Group 1 - The stock price of Shouxiangu (603896) closed at 22.65 yuan on August 22, 2025, an increase of 1.62% from the previous week [1] - The highest intraday price reached 22.92 yuan on August 22, while the lowest was 22.2 yuan on August 20 [1] - The current total market capitalization of Shouxiangu is 4.49 billion yuan, ranking 47th out of 67 in the traditional Chinese medicine sector and 3643rd out of 5152 in the A-share market [1] Group 2 - Shouxiangu provided a maximum pledge guarantee of 30 million yuan for its wholly-owned subsidiary, Jinhua Shouxiangu Pharmaceutical Co., Ltd., in collaboration with Zhejiang Wuyi Rural Commercial Bank [1] - The guarantee is part of a credit facility agreement that allows for financing from August 15, 2025, to May 1, 2027, without the need for counter-guarantees [1] - The company had previously approved a total credit limit of up to 800 million yuan at the 2024 annual shareholders' meeting, allowing for mutual guarantees among the company and its subsidiaries [1] Group 3 - The total amount of external guarantees provided by the listed company and its controlling subsidiaries is 19 million yuan, accounting for 8.27% of the latest audited net assets [1] - Jinhua Shouxiangu Pharmaceutical has a registered capital of 12.999 million yuan, with the company holding 100% equity [1] - As of March 31, 2025, the subsidiary's financial indicators showed total assets of 1.03377 billion yuan, total liabilities of 715.7963 million yuan, net assets of 317.9773 million yuan, operating income of 115.8209 million yuan, and net profit of 7.6159 million yuan [1]

Core Points - The company has entered into a maximum pledge contract with Zhejiang Wuyi Rural Commercial Bank to provide a guarantee for its wholly-owned subsidiary, Shouxiangu Pharmaceutical, with a maximum financing limit of RMB 30 million from August 15, 2025, to May 1, 2027 [1][4] - The company has approved a total credit limit of up to RMB 800 million for the year 2025, allowing for mutual guarantees between the company and its subsidiaries [1][4] - Shouxiangu Pharmaceutical is not a dishonest entity and has no significant issues affecting its debt repayment ability [1][4] Guarantee Details - The guarantee amount is RMB 30 million, covering all creditor rights arising from the contract, including principal, interest, and other related costs [2][4] - The guarantee period is from August 15, 2025, to May 1, 2027, and there is no counter-guarantee provided [4] - The necessity and reasonableness of the guarantee are justified by the stable operating condition of Shouxiangu Pharmaceutical, which has no major defaults or litigation issues [4] Cumulative Guarantee Information - As of the announcement date, the total external guarantees provided by the company amount to RMB 190 million, representing approximately 8.28% of the audited net assets attributable to shareholders as of December 31, 2024 [4]

Core Viewpoint - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. has announced a guarantee for its wholly-owned subsidiary, Jinhua Shouxiangu Pharmaceutical Co., Ltd., amounting to RMB 30 million, to support its financing needs with Wuyi Rural Commercial Bank [1][4]. Group 1: Guarantee Details - The guarantee amount provided is RMB 30 million, with a total guarantee balance of RMB 190 million for the subsidiary [1]. - The guarantee does not include any counter-guarantee [1]. - The total amount of external guarantees by the company is RMB 190 million, which does not exceed 50% of the company's latest audited net assets [1][4]. Group 2: Subsidiary Information - Jinhua Shouxiangu Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the company, established on August 27, 2003, with a registered capital of RMB 129.99 million [3]. - The subsidiary's main business includes the research and development of traditional Chinese medicine, as well as the sale of various food and health products [3]. Group 3: Financial Performance - As of the first quarter of 2025, the subsidiary reported total assets of RMB 1.03377 billion and total liabilities of RMB 715.80 million, resulting in a net asset value of RMB 317.98 million [3]. - The subsidiary's revenue for the year 2024 was RMB 462.89 million, with a net profit of RMB 2.41 million [3]. Group 4: Necessity and Reasonableness of Guarantee - The guarantee is deemed necessary to support the daily business development of the subsidiary, which is currently stable and does not have any significant litigation or arbitration issues [4]. - The company believes that the risk associated with this guarantee is manageable and does not harm the interests of the company or minority shareholders [4].